Mesothelioma - OmicsDI

Show results for

Unknown (1919)
Genomics (354)
Transcriptomics (235)
Clinical (71)
Proteomics (32)
Methylation profiling (8)
Other (7)
Metabolomics (2)
Genomic (1)

Organisms

Homo sapiens (287)
Mus musculus (48)
Methylocystis sp. (23)
Streptomyces coelicolor (23)
Pseudomonas aeruginosa PA103 (23)
Artibeus jamaicensis (23)
Morchella importuna (23)
Sclerotinia sclerotiorum (23)
Brassica napus (23)
Bartonella quintana JK 31 (23)
Bombyx mori (23)
Onchocerca volvulus (23)
Klebsiella pneumoniae (23)
Musca domestica (23)
Brugia malayi (23)
Schizosaccharomyces pombe (23)
Oryza sativa (23)
Cnidaria (23)
Streptomyces coelicolor A3(2) (23)
Sus scrofa (23)
Human immunodeficiency virus 1 (23)
Oryza sativa Indica Group (23)
Rattus norvegicus (18)
synthetic construct (2)
Solanum pimpinellifolium (1)
Populus nigra (1)
Schizosaccharomyces pombe (1)
Bos taurus (1)
Saccharomyces cerevisiae (1)
Danio rerio (1)

Organisms

Homo sapiens (160)
Mus musculus (35)
Rattus norvegicus (11)

Repository

ENA (250)
geo (184)
biostudies-arrayexpress (103)
EGA (62)
pride (23)
ExpressionAtlas (6)
iProX (2)
jPOST (2)
MassIVE (2)
dbGaP (1)
MetaboLights (1)
MetabolomicsWorkbench (1)
PanoramaPublic (1)
PeptideAtlas (1)

Tissue

Lung (9)
Pleura (4)
Pancreas (3)
Brain (3)
Liver (3)
Kidney (3)
Uterine cervix (2)
Breast (2)
Esophagus (2)
Stomach (2)
Ovary (2)
Uterus (2)
Urinary bladder (2)
Prostate gland (2)
Adrenal gland (2)
Testis (2)
Bile duct (2)
Bone marrow (2)
Lymph node (2)
Nasal septum (1)
Cartilage tissue (1)
Chordate pharynx (1)
Oral cavity (1)
Tongue (1)
Musculature (1)
Hematopoietic system (1)
Peripheral nervous system (1)
Vulva (1)
Mucosa (1)
Connective tissue (1)

Disease

Normal (6)
Mesothelioma (4)
Neuroblastoma (4)
Melanoma (4)
Chondrosarcoma (3)
Diffuse large B-cell lymphoma (3)
Acute myeloid leukemia (3)
Chronic myelogenous leukemia (3)
Osteosarcoma (3)
Large cell lung carcinoma (3)
Rhabdomyosarcoma (3)
Pancreatic carcinoma (3)
Ovarian carcinoma (3)
Non-small cell lung carcinoma (3)
Small cell lung carcinoma (3)
Multiple myeloma (3)
Renal cell carcinoma (3)
Pancreatic adenocarcinoma (3)
Gastric adenocarcinoma (3)
Hepatocellular carcinoma (3)
Squamous cell lung carcinoma (3)
Cervical squamous cell carcinoma (3)
Ovarian adenocarcinoma (3)
Lung adenocarcinoma (3)
Breast adenocarcinoma (3)
Breast carcinoma (3)
Gastric tubular adenocarcinoma (2)
Cecum adenocarcinoma (2)
Pancreatic adenosquamous carcinoma (2)
Colon carcinoma (2)

Technology Type

Mass Spectrometry (24)
Shotgun proteomics (15)
Bottom-up proteomics (6)
Illumina HiSeq 2000 (3)
Affinity purification coupled with mass spectrometry proteomics (3)
Data-dependent acquisition (2)
Illumina Oncoscan Array (1)
Illumina HiSeq 2000, Illumina HiSeq 2500, PacBio RS II (1)
HiSeq X Ten (1)
Mass spectrometry (1)
ESI (1)
SWATH MS (1)
Data-independent acquisition (1)

Instrument Platform

NextSeq 500 (8)
Nanostring GeoMx spatial profiler (2)
Illumina HiSeq 2500 (2)
Illumina HiSeq 4000 (2)
Agilent SureScan High Resolution scanner (1)
DNA Microarray Scanner (Model G2505C, Agilent Technologies) (1)
- (1)
Illumina NovaSeq 6000 (1)
LTQ Orbitrap (1)
Orbitrap Exploris 240 (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - negative - hilic (1)
Liquid Chromatography MS - positive - hilic (1)
LTQ Orbitrap Velos (1)

Publication Date

2025 (32)
2023 (25)
2024 (23)
2022 (21)
2021 (21)
2010 (20)
2011 (19)
2020 (18)
2014 (18)
2013 (18)
2018 (17)
2026 (15)
2012 (15)
2015 (14)
2019 (12)
2009 (11)
2016 (6)
2008 (6)
2017 (6)
2007 (3)
2006 (3)
2005 (2)

UNIPROT ID/AC

Q9NQ76 (1)
P16860 (1)
Q7Z5L0 (1)
Q5BKX8 (1)
Q02747 (1)
P35247 (1)
Q9BXU1 (1)
P78509 (1)
Q08ET2 (1)
P08476 (1)
Q9BQT9 (1)
Q96JN2 (1)
Q96FE7 (1)
P01258 (1)
P08913 (1)
Q7LGC8 (1)
P06734 (1)
O15389 (1)
Q9NQ38-3 (1)
Q9NQ38 (1)
Q96NZ9 (1)
Q96MK3 (1)
Q86UN3 (1)
Q13822-3 (1)
Q13822 (1)
P55058 (1)
P07307 (1)
Q9Y240 (1)
Q9UGM5 (1)
P48740-3 (1)

ENSEMBL ID

ENSG00000229353 (1)
ENSG00000170477 (1)

First Public Date

2014 (45)
2024 (32)
2023 (29)
2025 (27)
2021 (25)
2022 (19)
2026 (14)
2020 (14)
2018 (12)
2019 (10)
2015 (10)
2017 (5)
2013 (5)
2016 (2)
2012 (1)

Study status

Recruiting (29)
Completed (26)
Terminated (5)
Active, not recruiting (5)
Not provided (3)
Withdrawn (1)
Suspended (1)
Not yet recruiting (1)

Study type

Interventional (61)
Transcription profiling by array (55)
Methylation profiling by array (12)
RNA-seq of coding RNA (7)
Observational (6)
Comparative genomic hybridization by array (5)
Observational patient registry (4)
Unknown experiment type (3)
Genotyping by array (3)
Cell line - Two-color microarray (2)
Spatial transcriptomics by high-throughput sequencing (2)
ChIP-seq (2)
DNA-seq (2)
RNA-seq of total RNA (2)
Human - Two-color microarray (1)
ChIP-chip by tiling array (1)
One-color microarray (1)
ChIP-chip by array (1)
Transcription profiling by RT-PCR (1)
MicroRNA profiling by high throughput sequencing (1)
MicroRNA profiling by array (1)
RNA-seq of coding RNA from single cells (1)

Release Date

2022 (229)
2021 (218)
2024 (207)
2023 (203)
2020 (177)
2025 (162)
2019 (121)
2018 (120)
2017 (112)
2016 (104)
2015 (69)
2014 (65)
2013 (49)
2012 (45)
2011 (38)
2010 (33)
2009 (21)
2026 (19)
2008 (15)
2007 (5)
2005 (4)
2006 (2)
2004 (1)
2002 (1)
2000 (1)
1999 (1)

Lab affiliation

University of Vienna, Faculty of Chemistry, Department of Analytical Chemistry (5)
Department of Life Sciences, University of Mdoena and Reggio Emilia (1)
Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland (1)
Laboratory Head & Head of Inflammation Division, Walter and Eliza Hall Institute of Medical Research (WEHI), Australia 3052 (1)
Oncoproteomic Unit (1)
The Institute of Cancer Reaserach Moecular and Systems Oncology (1)
Department of Biochemistry and Molecular Biology and Infection and Immunity Program, Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia (1)
Cancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States (1)
Deputy Head (Research), Department of Biochemistry and Molecular Biology Head Immunoproteomics Laboratory (1)
Maisonneuve-Rosemont Hospital Research Center and Department of Medicine, University of Montréal, Montréal H3C 3J7, Québec, Canada (1)
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. (1)
Novo Nordisk Foundation Center for Protein Research (1)
Weill Cornell Medical College, New York City (1)
Biological Mass Spectrometry Lab Department of Translational Medicine (DiMeT) Center for Translational Research on Autoimmune & Allergic Diseases - CAAD University of Piemonte Orientale Corso Trieste 15/A, 28100, Novara, Italy (1)
Vancouver Prostate Centre (1)
Ruhr-Universität Bochum Medizinisches Proteom-Center AG Clinical Proteomics (1)
The Netherlands Cancer Institute Proteomics Facility (1)
European Institute of Oncology, Milan (1)
Dept. Oncology-Pathology, SciLifeLab, Karolinska Institutet, Stockholm, Sweden (1)

Location

United States (49)
United Kingdom (9)
Spain (8)
Italy (7)
South Korea (6)
France (6)
Australia (6)
Germany (5)
Belgium (5)
Canada (5)
Switzerland (5)
Denmark (4)
Taiwan (4)
Japan (4)
Norway (3)
Russia (3)
China (3)
Poland (3)
Netherlands (3)
Singapore (2)
Israel (2)
Brazil (2)
Austria (2)
Africa (1)
Oceania (1)
South America (1)
Guam (1)
Finland (1)
Iran (1)
South Africa (1)

Keyword

Pembrolizumab (8)
Metastatic (5)
SCCHN (4)
Kidney cancer (4)
Pemetrexed (4)
CRC (4)
Nivolumab (4)
Osteosarcoma (3)
Mitomycin (3)
HIPEC (3)
Renal cell carcinoma (RCC) (3)
RCC (3)
Urothelial carcinoma (3)
Cyclophosphamide (3)
Phase 1 (3)
Atezolizumab (3)
Cisplatin (3)
Lung (3)
Pancreatic (3)
Tislelizumab (3)
Ipilimumab (3)
Chemotherapy (3)
Irinotecan (3)
Avelumab (3)
Immunotherapy (3)
Adenosarcoma (2)
Carcinoma, Small Cell (2)
Fibrosarcoma (2)
Hemangiosarcoma (2)
Liposarcoma (2)

Previous page
1 / 263
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 263
Next page

Sort by:

Relevance

Page size

De Novo Pyrimidine Synthesis Is a Collateral Metabolic Vulnerability in NF2-deficient Mesothelioma

Pleural mesothelioma (PM) is one of the deadliest cancers, with limited therapeutic options due to its therapeutically intractable genome, which is characterized by the functional inactivation of tumor suppressor genes (TSGs) and high tumor heterogeneity, including diverse metabolic adaptations. ...

2025-07-07 | MTBLS12461 | MetaboLights

Gene expression changes between primary mesothelioma tumour cells and commercially available cell lines, compared to normal primary mesothelial cells

Malignant mesothelioma (MM) is an aggressive, fatal tumour strongly associated with asbestos exposure. There is an urgent need to improve MM patient outcomes and this requires functionally validated pre-clinical models. Mesothelioma-derived cell lines provide an essential and robust tool widely used...

ORGANISM(S): Homo sapiens

2018-02-01 | E-MTAB-6351 | biostudies-arrayexpress

Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma

This SuperSeries is composed of the following subset Series: GSE20989: Mesothelioma integrative genomics: DNA methylation GSE21057: Copy number alterations in pleural mesothelioma Refer to individual Series

ORGANISM(S): Homo sapiens

2010-07-01 | E-GEOD-21058 | biostudies-arrayexpress

Lung adenocarcinoma and mesothelioma DNA methylation

Pathologic differentiation of tissue of origin in tumors found in the lung can be challenging, with differentiation of mesothelioma and lung adenocarcinoma emblematic of this problem. Indeed, proper classification is essential for determination of treatment regimen for these diseases, making accurat...

ORGANISM(S): Homo sapiens

2010-06-25 | E-GEOD-16559 | biostudies-arrayexpress

Chromosomal aberration of asbestos-induced malignant mesothelioma in rats

Exposure to asbestos is a risk for malignant mesothelioma in humans. We carried out array comparative genomic hybridization (CGH) analysis in a rat model by repeated intraperitoneal injections of three types of asbestos including chrysotile, crocidolite and amosite. We found a common chromosomal del...

ORGANISM(S): Rattus norvegicus

2012-08-13 | E-GEOD-36577 | biostudies-arrayexpress

Transcription profiling by array of mesothelioma pre- and post-resistance biopsies in order to determine a resistance signature to pemetrexed/carboplatin treatment

Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Innate and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the first time a genome...

ORGANISM(S): Homo sapiens

2012-10-01 | E-MTAB-1109 | biostudies-arrayexpress

Transcription profiling of two mesothelioma cell lines (MPP89 and REN), and of HMC-TERT non tumoral mesothelial cells

miRNA profile analysis of two mesothelioma cell lines (MPP89 and REN), and of HMC-TERT non tumoral mesothelial cells

ORGANISM(S): Homo sapiens

2008-10-09 | E-MEXP-1699 | biostudies-arrayexpress

Transcription profiling of human mesothelioma cells MPP-89 REN compared to mesothelial cells HMC-TERT

gene expression profile of mesothelioma cells (MPP-89; REN) compared to mesothelial cells (HMC-TERT)

ORGANISM(S): Homo sapiens

2008-10-09 | E-MEXP-1701 | biostudies-arrayexpress

Transcription profiling of human mesothelioma cells (MPP-89, REN) compared to mesothelial cells (HMC-TERT)

gene expression profiles of mesothelioma cells (MPP-89, REN) compared to mesothelial cells (HMC-TERT)

ORGANISM(S): Homo sapiens

2008-10-09 | E-MEXP-1700 | biostudies-arrayexpress

Gene Expression Profiling of Malignant Peritoneal Mesothelioma Patient Tumor Samples

Gene expression profiles were generated from 41 consecutive surgically resected fresh frozen malignant peritoneal mesothelioma patient tumor samples to identify molecular prognostic factors. Patient tumor samples hybridized against the common reference (complementary DNA generated from human univers...

ORGANISM(S): Homo sapiens

2010-09-27 | E-GEOD-15627 | biostudies-arrayexpress

Previous page
1 / 263
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 263
Next page

Sort by:

Relevance

Page size

2629 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

ENSEMBL ID

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets